english.prescrire.org > Prescrire International > N°193 - May 2018

n°193

May 2018

Issue Contents
Editorial

Free  New cancer drugs: poorly evaluated, not very effective

p.115

Marketing Authorisations


Arsenic trioxide (Trisenox°) and acute promyelo­cytic leukaemia

p.117-118
First-line choice for patients at low or intermediate risk of relapse

Elotuzumab (Empliciti°) combination therapy for relapsed or refractory multiple myeloma

p.119-120
No proven therapeutic advance at this point

Blinatumomab (Blincyto°) and acute lymphoblastic leukaemia in adults

p.121-122
May offer a greater chance of receiving a transplant, but many severe adverse effects

INN Common stem: -nidazole

p.122

Dabrafenib (Tafinlar°) and trametinib (Mekinist°) combined for certain types of lung cancer

p.123
No proven impact on survival

Lacosamide (Vimpat°) monotherapy and focal epilepsy

p.124-125
No better than existing alternatives

Adverse Effects


Metopimazine: cardiac disorders

p.126-129

Inset. Too many patients exposed to metopimazine in France

p.127

Inset. Managing nausea and vomiting caused by gastroenteritis

p.128

Ketoprofen gel: serious photosensitivity reactions once again

p.129

Free  In utero exposure to diethylstilbestrol (DES): psychiatric disorders

p.130

Acid-based wart treatments: burns and sequelae

p.131-132

Oxetorone: chronic diarrhoea

p.132

Reviews


Herpes zoster during pregnancy

p.133-135
Aciclovir when an antiviral is justified

End-of-life mental confusion

p.136
Neuroleptics should not be used

Outlook


Exploratory trials, surrogate endpoints: not a robust basis for marketing authorisation

p.137-138

Selecting reliable guidelines: a 10-year analysis of France's official clinical recommendations

p.139
Poor documentation, adverse effects underestimated

Masthead


Free  Masthead

p.114

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe